28 min listen
Axonics’ Non-Drug Incontinence Therapy + How AI Can Be Used to Study the Side Effects of Drugs
Axonics’ Non-Drug Incontinence Therapy + How AI Can Be Used to Study the Side Effects of Drugs
ratings:
Length:
38 minutes
Released:
May 3, 2023
Format:
Podcast episode
Description
In this episode, Vera talked about how a couple of direct-to-consumer TV commercials have helped a medical device company, Axonics, establish its reputation in the non-drug incontinence therapy space. Around 87 million adults in the US and Europe have overactive bladder and it is estimated that an additional 40 million adults have fecal incontinence. Axonics offers innovative sacral neuromodulation (SNM) systems that are approved by the US Food and Drug Administration (FDA) for the treatment of bladder and bowel dysfunction. The team discussed Axonics Therapy and the occurrence of non-drug (medical device) TV ads.Vera and the team also discussed how two companies, Cerner Enviza and John Snow Labs, are teaming up with the FDA to use AI tools to better understand the side effects of drugs. This project is part of the FDA’s Sentinel Initiative to evaluate the effects of medicines on real-world populations. Hear more about how Cerner Enviza and John Snow Labs will use AI to explore the mental health side effects of a commonly prescribed asthma drug, Singulair (montelukast)Read the full articles here:Axonics Touts Non-Drug Incontinence Therapy in TV AdsHow Cerner Enviza Will Use AI To Study the Mental Health Side Effects of MontelukastFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @XtalksFacebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured
Released:
May 3, 2023
Format:
Podcast episode
Titles in the series (100)
Mask-Associated Dry Eye + Droplet Micron Insulin Needle by Xtalks Life Science Podcast